Zyprexa

Analysts surveyed by Thomson Financial predicted earnings of $3.08 in 2006.

Lilly shares closed yesterday at $53.41, up $1.20 or 2 percent.

The company said it expects to submit five new products to government regulators by 2009.

It plans to submit an application for Arxxant, a drug to prevent blindness caused by diabetes, to regulators by the end of February.

Another drug that has piqued analysts' interest is the blood thinner Prasugrel, which the company expects to submit in 2007.

Analysts agree Prasugrel has blockbuster potential.

Lilly also said it plans to reduce the average development cost for drugs by one-third to $800 million from $1.2 billion by the end of the decade.

^^ Back to top E-mail this Print this Subscribe RSS feeds .gcitopjobs a:link {font-family: verdana, sans-serif; font-size: 10px; text-decoration: none; color: #000099} .gcitopjobs a:visited {font-family: verdana, sans-serif; font-size: 10px; text-decoration: none; color: #000099} .gcitopjobs a:active {font-family: verdana, sans-serif; font-size: 10px; text-decoration: none; color: #990000} .gcitopjobs a:hover {font-family: verdana, sans-serif; font-size: 10px; text-decoration: none; color: #990000} Home Cars ...

It plans to submit an application for Arxxant, a drug to prevent blindness caused by diabetes, to regulators by the end of February.

Some analysts were expecting a submission later this year but don't believe the delay is significant.Another drug that has piqued analysts' interest is blood thinner Prasugrel, which the company expects to submit in 2007.

Analysts agree Prasugrel has blockbuster potential.Lilly also said it plans to reduce the average development cost for new drugs by one-third to $800 million from $1.2 billion by the end of the decade.Lilly shares rose $1.20, or 2.3 percent, to close at $53.41 Friday on the New York Stock Exchange.

More Business Headlines In move to cut costs, even profitable companies look to freeze pensions Hurricane, disease drive up Florida orange juice prices Natural gas prices retreat after touching new high overnight Vioxx trial jurors deliberate for second day with no verdict Stocks end modestly higher on lower oil Peru trade deal angers Michigan asparagus growers U.S.

trade envoy expects eventual WTO deal, despite cur...

Analysts surveyed by Thomson Financial predicted earnings of $3.08 in 2006.The company said it expects to submit five new products to government regulators for review in the next four years as it seeks new indications for existing products.

It plans to submit an application for Arxxant, a drug to prevent blindness caused by diabetes, to regulators by the end of February.

Some analysts were expecting a submission later this year but don't believe the delay is significant.Another drug that has piqued analysts' interest is blood thinner Prasugrel, which the company expects to submit in 2007.

Analysts agree Prasugrel has blockbuster potential.Lilly also said it plans to reduce the average development cost for new drugs by one-third to $800 million from $1.2 billion by the end of the decade.Lilly shares rose $1.20, or 2.3 percent, to close at $53.41 Friday on the New York Stock Exchange.

Click here for daily newspaper delivery Click here for daily online news alerts Click here to send a Letter to the Editor Click here to send an Announcement Comments On This Story Add Your Comments or Letter to the Editor First name only.

Comments including last names, contact addresses, email addresses or phone numbers will be deleted.

All comments are screen...